buntanetap/posiphen + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease, Idiopathic

Conditions

Parkinson's Disease, Idiopathic

Trial Timeline

Aug 3, 2022 → Dec 4, 2023

NCT ID

NCT05357989

About buntanetap/posiphen + Placebo

buntanetap/posiphen + Placebo is a phase 3 stage product being developed by Annovis Bio for Parkinson's Disease, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT05357989. Target conditions include Parkinson's Disease, Idiopathic.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease, Idiopathic were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06709014	Phase 3	Recruiting	Feb 4, 2025	Jun 1, 2028	Early Alzheimers Disease
NCT05686044	Phase 2/3	Completed	Apr 1, 2023	Feb 13, 2024	Alzheimer Disease
NCT05357989	Phase 3	Completed	Aug 3, 2022	Dec 4, 2023	Parkinson's Disease, Idiopathic

Competing Products

20 competing products in Parkinson's Disease, Idiopathic

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40